p53 genes

Summary

Summary: Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.

Top Publications

  1. ncbi p53, the cellular gatekeeper for growth and division
    A J Levine
    Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, New Jersey 08544, USA
    Cell 88:323-31. 1997
  2. ncbi p53 mutations in human cancers
    M Hollstein
    Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Science 253:49-53. 1991
  3. ncbi Live or let die: the cell's response to p53
    Karen H Vousden
    Regulation of Cell Growth Laboratory, National Cancer Institute at Frederick, 1050 Boyles Street, Frederick, Maryland 21702, USA
    Nat Rev Cancer 2:594-604. 2002
  4. ncbi Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
    L A Donehower
    Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030
    Nature 356:215-21. 1992
  5. ncbi Transcriptional control of human p53-regulated genes
    Todd Riley
    The Institute for Advanced Study, Princeton, New Jersey, USA
    Nat Rev Mol Cell Biol 9:402-12. 2008
  6. ncbi A system for stable expression of short interfering RNAs in mammalian cells
    Thijn R Brummelkamp
    Division of Molecular Carcinogenesis, Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
    Science 296:550-3. 2002
  7. ncbi The IARC TP53 database: new online mutation analysis and recommendations to users
    Magali Olivier
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Hum Mutat 19:607-14. 2002
  8. ncbi p53 mutant mice that display early ageing-associated phenotypes
    Stuart D Tyner
    Cell and Molecular Biology Program, Baylor College of Medicine, Houston, TX 77030, USA
    Nature 415:45-53. 2002
  9. ncbi Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
    Vassilis G Gorgoulis
    Department of Histology and Embryology, School of Medicine, University of Athens, Athens GR 11527, Greece
    Nature 434:907-13. 2005
  10. ncbi Requirement for p53 and p21 to sustain G2 arrest after DNA damage
    F Bunz
    The Howard Hughes Medical Institute and The Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA
    Science 282:1497-501. 1998

Detail Information

Publications273 found, 100 shown here

  1. ncbi p53, the cellular gatekeeper for growth and division
    A J Levine
    Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, New Jersey 08544, USA
    Cell 88:323-31. 1997
  2. ncbi p53 mutations in human cancers
    M Hollstein
    Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Science 253:49-53. 1991
    ..These differences may reflect the etiological contributions of both exogenous and endogenous factors to human carcinogenesis...
  3. ncbi Live or let die: the cell's response to p53
    Karen H Vousden
    Regulation of Cell Growth Laboratory, National Cancer Institute at Frederick, 1050 Boyles Street, Frederick, Maryland 21702, USA
    Nat Rev Cancer 2:594-604. 2002
  4. ncbi Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
    L A Donehower
    Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030
    Nature 356:215-21. 1992
    ....
  5. ncbi Transcriptional control of human p53-regulated genes
    Todd Riley
    The Institute for Advanced Study, Princeton, New Jersey, USA
    Nat Rev Mol Cell Biol 9:402-12. 2008
    ..In addition, we present the most comprehensive list so far of human p53-regulated genes and their experimentally validated, functional binding sites that confer p53 regulation...
  6. ncbi A system for stable expression of short interfering RNAs in mammalian cells
    Thijn R Brummelkamp
    Division of Molecular Carcinogenesis, Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
    Science 296:550-3. 2002
    ..Therefore, the pSUPER vector constitutes a new and powerful system to analyze gene function in a variety of mammalian cell types...
  7. ncbi The IARC TP53 database: new online mutation analysis and recommendations to users
    Magali Olivier
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Hum Mutat 19:607-14. 2002
    ..In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users...
  8. ncbi p53 mutant mice that display early ageing-associated phenotypes
    Stuart D Tyner
    Cell and Molecular Biology Program, Baylor College of Medicine, Houston, TX 77030, USA
    Nature 415:45-53. 2002
    ..A second line of transgenic mice containing a temperature-sensitive mutant allele of p53 also exhibits early ageing phenotypes. These data suggest that p53 has a role in regulating organismal ageing...
  9. ncbi Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
    Vassilis G Gorgoulis
    Department of Histology and Embryology, School of Medicine, University of Athens, Athens GR 11527, Greece
    Nature 434:907-13. 2005
    ..We analysed a panel of human lung hyperplasias, all of which retained wild-type p53 genes and had no signs of gross chromosomal instability, and found signs of a DNA damage response, including histone ..
  10. ncbi Requirement for p53 and p21 to sustain G2 arrest after DNA damage
    F Bunz
    The Howard Hughes Medical Institute and The Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA
    Science 282:1497-501. 1998
    ..Thus, p53 and p21 appear to be essential for maintaining the G2 checkpoint in human cells...
  11. ncbi p53 is required for radiation-induced apoptosis in mouse thymocytes
    S W Lowe
    Department of Biology, Massachusetts, Cambridge 02139
    Nature 362:847-9. 1993
    ..These results demonstrate that p53 is required for radiation-induced cell death in the thymus but is not necessary for all forms of apoptosis...
  12. pmc p53 isoforms can regulate p53 transcriptional activity
    Jean Christophe Bourdon
    Department of Surgery, Cancer Research UK Cell Transformation Research Group, University of Dundee, Ninewells Hospital, Scotland, UK
    Genes Dev 19:2122-37. 2005
    ..The differential expression of the p53 isoforms in human tumors may explain the difficulties in linking p53 status to the biological properties and drug sensitivity of human cancer...
  13. ncbi DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Nature 434:864-70. 2005
    ..Mutations compromising this checkpoint, including defects in the ATM-Chk2-p53 pathway, might allow cell proliferation, survival, increased genomic instability and tumour progression...
  14. pmc Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
    Shunsuke Kato
    Department of Clinical Oncology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai 980 8575, Japan
    Proc Natl Acad Sci U S A 100:8424-9. 2003
    ..This high-resolution mutation analysis allows evaluation of previous predictions and hypotheses through interrelation of function, structure and mutation...
  15. ncbi p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
    A Yang
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cell 2:305-16. 1998
    ..We demonstrate that these truncated p63 variants can act as dominant-negative agents toward transactivation by p53 and p63, and we suggest the possibility of physiological interactions among members of the p53 family...
  16. ncbi Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
    Gene A Lang
    Department of Molecular Genetics, Section of Cancer Genetics, The University of Texas MD Anderson Cancer Center and The University of Texas Graduate School of Biomedical Sciences, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cell 119:861-72. 2004
    ..These results provide in vivo validation for the gain-of-function properties of certain p53 missense mutations and suggest a mechanistic basis for these phenotypes...
  17. pmc tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
    Stephane Berghmans
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 102:407-12. 2005
    ....
  18. ncbi Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
    Gerd P Pfeifer
    Division of Biology, Beckman Research Institute of the City of Hope, Duarte, California, CA 91010, USA
    Oncogene 21:7435-51. 2002
    ..The available data suggest that p53 mutations in lung cancers can be attributed to direct DNA damage from cigarette smoke carcinogens rather than to selection of pre-existing endogenous mutations...
  19. ncbi A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
    M C Marin
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Nat Genet 25:47-54. 2000
    ..Thus, inactivation of p53 family members may contribute to the biological properties of a subset of p53 mutants, and a polymorphic residue within p53 affects mutant behaviour...
  20. ncbi Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years
    Shan Wang-Gohrke
    Department of Obstetrics and Gynaecology, Molecular Biology Laboratory, University of Ulm, Germany
    Pharmacogenetics 12:269-72. 2002
    ..Our data suggest that inheritance of an intronic polymorphism in the p53 gene increases breast cancer risk appreciably in women by the age of 50 years with a family history of breast cancer in the German population...
  21. ncbi PML is a direct p53 target that modulates p53 effector functions
    Elisa de Stanchina
    Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA
    Mol Cell 13:523-35. 2004
    ..These results identify an additional element of PML regulation and establish PML as a mediator of p53 tumor suppressor functions...
  22. ncbi Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors
    J A Lopez-Guerrero
    Department of Pathology, School of Medicine, University of Valencia, Valencia, Spain
    Lab Invest 81:803-14. 2001
    ..This fact points to an important role of the G(1)/S cell cycle checkpoint dysregulation in the pathogenesis of EFT...
  23. ncbi Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
    K M Dameron
    Department of Microbiology Immunology, Northwestern University Medical School, Chicago, IL 60611
    Science 265:1582-4. 1994
    ..These data indicate that, in fibroblasts, wild-type p53 inhibits angiogenesis through regulation of TSP-1 synthesis...
  24. ncbi Molecular portraits of breast cancer: tumour subtypes as distinct disease entities
    Therese Sørlie
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo, Norway
    Eur J Cancer 40:2667-75. 2004
    ..This Review describes advances in the characterisation of breast tumour phenotypes using DNA microarrays and the identification of five subtypes of breast cancer with significant clinical implications...
  25. ncbi Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation
    X Xu
    Genetics of Development and Disease Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Genet 22:37-43. 1999
    ..Our results demonstrate that disruption of Brca1 causes genetic instability and triggers further alterations, including the inactivation of p53, that lead to tumour formation...
  26. ncbi Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
    D Malkin
    Division of Molecular Genetics, Massachusetts General Hospital Cancer Center, Charlestown 02129
    Science 250:1233-8. 1990
    ..The frequency of germ line p53 mutations can now be examined in additional families with LFS, and in other cancer patients and families with clinical features that might be attributed to the mutation...
  27. ncbi p53 regulates mitochondrial respiration
    Satoaki Matoba
    Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Science 312:1650-3. 2006
    ..That SCO2 couples p53 to mitochondrial respiration provides a possible explanation for the Warburg effect and offers new clues as to how p53 might affect aging and metabolism...
  28. ncbi Locus-specific mutation databases: pitfalls and good practice based on the p53 experience
    Thierry Soussi
    Université P M Curie, 4 place Jussieu, 75005 Paris, France
    Nat Rev Cancer 6:83-90. 2006
    ..However, there are several biases in this database that can lead to serious erroneous interpretations. We describe several rules for mutation database management that could benefit the entire scientific community...
  29. ncbi MDM2 is a central node in the p53 pathway: 12 years and counting
    Gareth L Bond
    School of Natural Sciences, Institute for Advanced Study, Princeton, NJ 08540, USA
    Curr Cancer Drug Targets 5:3-8. 2005
    ..The p53 gene is mutated in 50% of all human tumors, but in those tumors that retain wild type p53, inhibiting Mdm2 activity could activate p53 tumor suppression and therefore provide a therapeutic strategy for the treatment of cancer...
  30. ncbi Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
    S Geisler
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Cancer Res 61:2505-12. 2001
    ..Our findings are consistent with the hypothesis that other defects may act in concert with loss of p53 function, causing resistance to doxorubicin in breast cancers...
  31. pmc Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding
    E Shaulian
    Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
    Mol Cell Biol 12:5581-92. 1992
    ..These findings suggest that p53-mediated transformation may operate through a dominant negative mechanism, involving the generation of DNA binding-incompetent oligomers...
  32. ncbi Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations
    Y Cho
    Cellular Biochemistry and Biophysics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Science 265:346-55. 1994
    ..The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it...
  33. ncbi The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma
    Yuan Hong
    Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Cancer Res 65:9582-7. 2005
    ..60; 95% CI, 1.00-2.64; P = 0.049). The P53 and MDM2 polymorphisms may be genetic determinants for the development of ESCC...
  34. pmc P53 germline mutations in childhood cancers and cancer risk for carrier individuals
    A Chompret
    , Institute Gustave Roussy, Villejuif, France
    Br J Cancer 82:1932-7. 2000
    ..The risk of cancer associated with such mutations is very high and no evidence of low penetrance mutation was found. These mutations are frequently inherited but de novo mutations are not rare...
  35. ncbi Post-translational modification of p53 in tumorigenesis
    Ann M Bode
    The Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, Minnesota 55912, USA
    Nat Rev Cancer 4:793-805. 2004
    ..A thorough understanding of p53 will be extremely useful in the development of new strategies for treating and preventing cancer, including restoration of p53 function and selective killing of tumours with mutant TP53...
  36. ncbi Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
    Magali Olivier
    IARC, Lyon, Cedex 8, France
    Cancer Res 63:6643-50. 2003
    ..004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families...
  37. ncbi p53 as a mutagen test in breast cancer
    Kathleen A Hill
    Department of Molecular Genetics, City of Hope National Medical Center, Duarte, California, USA
    Environ Mol Mutagen 39:216-27. 2002
    ..Mutagen tests and mutation load measurements are useful tools to identify the role of mutagens in breast cancer...
  38. ncbi p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Natl Cancer Inst 94:681-90. 2002
    ..We also examined the functionality of the p53 variants in apoptosis and DNA repair...
  39. ncbi Structural biology of the tumor suppressor p53
    Andreas C Joerger
    Medical Research Council Centre for Protein Engineering, Cambridge, United Kingdom
    Annu Rev Biochem 77:557-82. 2008
    ..p53 emerges as a paradigm for a more general understanding of the structural organization of modular proteins and the effects of disease-causing mutations...
  40. ncbi Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
    J Jonkers
    Division of Molecular Genetics and Centre of Biomedical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    Nat Genet 29:418-25. 2001
    ..Our results show that inactivation of BRCA2 and of p53 combine to mediate mammary tumorigenesis, and indicate that disruption of the p53 pathway is pivotal in BRCA2-associated breast cancer...
  41. ncbi The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
    Patrick Dumont
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA
    Nat Genet 33:357-65. 2003
    ..These data indicate that the two polymorphic variants of p53 are functionally distinct, and these differences may influence cancer risk or treatment...
  42. ncbi Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements
    Ekkehard Kunze
    Center of Pathology, University of Gottingen, D 37099 Göttingen, Germany
    Int J Mol Med 17:3-13. 2006
    ....
  43. ncbi MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth
    David C Corney
    Department of Biomedical Sciences and Microarray Core Facility, Cornell University, Ithaca, New York, USA
    Cancer Res 67:8433-8. 2007
    ..Taken together, these results show the existence of a novel mechanism by which p53 suppresses such critical components of neoplastic growth as cell proliferation and adhesion-independent colony formation...
  44. pmc Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts
    Maher A Noureddine
    Environmental Genomics Group, Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA
    PLoS Genet 5:e1000462. 2009
    ....
  45. ncbi p53 suppresses the self-renewal of adult neural stem cells
    Konstantinos Meletis
    Department of Cell and Molecular Biology, Medical Nobel Institute, Karolinska Institute, SE 171 77 Stockholm, Sweden
    Development 133:363-9. 2006
    ..These data implicate p53 as a suppressor of tissue and cancer stem cell self-renewal...
  46. ncbi p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome
    Kaisa Sotamaa
    Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:6840-4. 2005
    ..We studied the influence of both polymorphisms on age of onset in Lynch syndrome and of the p53 polymorphism also in sporadic colorectal cancer...
  47. ncbi The p53 codon 72 polymorphism and lung cancer risk
    R Fan
    Department of Environmental Health Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 9:1037-42. 2000
    ..The p53 gene may modulate the response to environment carcinogens and thereby affect the risk of developing lung adenocarcinoma...
  48. ncbi Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53
    J Parant
    The University of Texas M D Anderson Cancer Center, Department of Molecular Genetics, Section of Cancer Genetics, Box 11, 1515 Holcombe Blvd, Houston, Texas, USA
    Nat Genet 29:92-5. 2001
    ..These data define a new pathway of p53 regulation and raise the possibility that increased MDM4 levels and the resulting inactivation of p53 contribute to the development of human tumors...
  49. ncbi A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
    Federica Gemignani
    International Agency for Research on Cancer, Lyon 69372, France
    Oncogene 23:1954-6. 2004
    ..However, we found reduced levels of TP53 mRNA associated with the A2 allele. In conclusion, the epidemiological study suggests a role for p53PIN3 in tumorigenesis, supported by the in vitro characterization of this variant...
  50. ncbi The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
    B K Linderholm
    Department of Oncology, Radiumhemmet, Karolinska Institute and Hospital, Stockholm, Sweden
    Cancer Res 61:2256-60. 2001
    ..4 and 2.1 for BCCS and RFS, respectively. VEGF expression is related to p53 status in human breast cancer patients. Combining VEGF with p53 status resulted in better prognostic prediction...
  51. pmc Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
    C M Eischen
    Department of Biochemistry, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Genes Dev 13:2658-69. 1999
    ..Therefore, Myc activation strongly selects for spontaneous inactivation of the ARF-Mdm2-p53 pathway in vivo, cancelling its protective checkpoint function and accelerating progression to malignancy...
  52. pmc Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk
    Shih Jen Hwang
    Section of Clinical Cancer Genetics, Department of Molecular Genetics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hum Genet 72:975-83. 2003
    ..These results quantitatively illustrated the spectrum of cancer risk in germline p53 mutation carriers and will provide valuable reference for the evaluation and treatment of patients with cancer...
  53. pmc A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
    C Gaiddon
    Department of Biological Sciences, Columbia University, New York, New York 10027, USA
    Mol Cell Biol 21:1874-87. 2001
    ....
  54. pmc Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation
    S Venkatachalam
    Division of Molecular Virology and Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
    EMBO J 17:4657-67. 1998
    ..These results indicate that loss of both p53 alleles is not a prerequisite for tumor formation and that mere reduction in p53 levels may be sufficient to promote tumorigenesis...
  55. pmc Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells
    Timothy F Burns
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Mol Cell Biol 23:5556-71. 2003
    ..Finally, these studies suggest that disruption of Snk/Plk2 may be of therapeutic value in sensitizing paclitaxel-resistant tumors...
  56. ncbi Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines
    Helena Shaked
    Department of Molecular Biology, Microarray Service Laboratory, The Core Research Facility, and Lautenberg Center for General and Tumor Immunology, Hebrew University Medical School, Jerusalem, Israel
    Cancer Res 68:9671-7. 2008
    ..Our results suggest that nonactivated p53 has limited binding activity, whereas upon activation it binds to essentially all its targets. Additional triggers are most likely required to activate the transcriptional program of p53...
  57. ncbi Sequence of molecular genetic events in colorectal tumorigenesis
    P Laurent-Puig
    Laboratoire de Toxicologie Moléculaire, INSERM U490, Paris, France
    Eur J Cancer Prev 8:S39-47. 1999
    ..In the p53 pathway LOH-positive tumours showed frequent p53 mutation, whereas MSI-positive tumours demonstrated BAX (BCL-2-associated X protein)-inactivating mutation. These alterations contribute to the adenoma-carcinoma transition...
  58. ncbi p53 enters the microRNA world
    Heiko Hermeking
    Molecular Oncology, Max Planck Institute of Biochemistry, Am Klopferspitz 18, D 82152 Martinsried, Germany
    Cancer Cell 12:414-8. 2007
    ..The initial evidence suggesting that miR-34 genes are central mediators of p53 function is summarized here...
  59. ncbi TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence
    Thijn R Brummelkamp
    Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Biol Chem 277:6567-72. 2002
    ..These data suggest that the hypoproliferative features of this genetic disorder may be caused, at least in part, by deregulated expression of p14(ARF)...
  60. ncbi Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants
    M S Greenblatt
    Department of Medicine, Vermont Cancer Center, University of Vermont, Burlington, VT 05401, USA
    Oncogene 22:1150-63. 2003
    ..These data validate our hypothesis that detailed evolutionary analyses help predict the consequences of missense amino-acid variants...
  61. ncbi Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status
    Chiara Menin
    IST Genova, Azienda Ospedaliera di Padova and Istituto Oncologico Veneto, Padova, Italy
    J Natl Cancer Inst 98:285-8. 2006
    ..0 years, 95% confidence interval = 1.0 to 16.0 years; P = .03 [two-sided Wilcoxon rank sum test]). Our data indicate that MDM2-SNP309 is a modifier of the age at colorectal cancer onset for patients whose tumors have a wild-type p53 gene...
  62. pmc An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma
    R C Ribeiro
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 98:9330-5. 2001
    ..Therefore, this inherited R337H p53 mutation represents a low-penetrance p53 allele that contributes in a tissue-specific manner to the development of pediatric ACC...
  63. pmc Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer
    Sandra Costa
    Life and Health Sciences Research Institute, School of Health Science, University of Minho, Braga, 4710 057, Portugal
    BMC Cancer 8:32. 2008
    ..The purpose of this study was to evaluate the role of Arg72Pro and PIN3 Ins16bp polymorphisms in TP53 gene as genetic susceptibility and predictive markers to breast cancer...
  64. ncbi Regulation of p53 activity through lysine methylation
    Sergei Chuikov
    Howard Hughes Medical Institute, Division of Nucleic Acids Enzymology, Department of Biochemistry, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    Nature 432:353-60. 2004
    ..The crystal structure of a ternary complex of Set9 with a p53 peptide and the cofactor product S-adenosyl-l-homocysteine (AdoHcy) provides the molecular basis for recognition of p53 by this lysine methyltransferase...
  65. ncbi p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis
    T Soussi
    Institut Curie, UMR 218 CNRS, Paris, France
    Hum Mutat 15:105-13. 2000
    ..This software includes an optimized structure to assist and secure data entry and to allow the input of various clinical data...
  66. pmc Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
    P D Pharoah
    CRC Human Cancer Genetics Group and Department of Oncology, University of Cambridge, UK
    Br J Cancer 80:1968-73. 1999
    ..Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in prognostication, and possibly choice of therapy...
  67. ncbi Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
    David W Kindelberger
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Surg Pathol 31:161-9. 2007
    ....
  68. pmc Regional analysis of p53 mutations in rheumatoid arthritis synovium
    Yuji Yamanishi
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego School of Medicine, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 99:10025-30. 2002
    ..A relatively low percentage of cells containing p53 mutations can potentially affect neighboring cells and enhance inflammation through the elaboration of proinflammatory cytokines...
  69. ncbi Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome
    S Srivastava
    Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 4799
    Nature 348:747-9. 1990
    ..The NSF cell lines with the mutation also retained the normal p53 allele. This inherited p53 mutation may predispose the members of this family to increased susceptibility to cancer...
  70. ncbi Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein
    J E Landers
    Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia 19104 6069, USA
    Cancer Res 57:3562-8. 1997
    ..These data provide a quantitative explanation for the overexpression of mdm2 proteins in this class of human tumors...
  71. pmc Identification of a novel p53 functional domain that is necessary for efficient growth suppression
    K K Walker
    Department of Molecular Biology, Prineton University, NJ 08544, USA
    Proc Natl Acad Sci U S A 93:15335-40. 1996
    ....
  72. ncbi Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors
    M L Slattery
    Health Research Center, Department of Family and Preventive Medicine, University of Utah, Salt Lake City, USA
    J Natl Cancer Inst 92:1831-6. 2000
    ..It is unknown whether lifestyle factors associated with colon cancer, such as physical activity, body size, cigarette smoking, or use of aspirin and/or nonsteroidal anti-inflammatory drugs, contribute to MSI in sporadic tumors...
  73. pmc DNA substrate dependence of p53-mediated regulation of double-strand break repair
    Nuray Akyüz
    Universitatsfrauenklinik, D 89075 Ulm, Germany
    Mol Cell Biol 22:6306-17. 2002
    ..These results suggest that p53 plays a role in restraining DNA exchange between imperfectly homologous sequences and thereby in suppressing tumorigenic genome rearrangements...
  74. ncbi Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer
    Zongxiang Zhou
    Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853 6401, USA
    Cancer Res 66:7889-98. 2006
    ..The new genetically defined model should be particularly valuable for providing new molecular insights into the pathogenesis of human prostate cancer...
  75. ncbi Tumor spectrum analysis in p53-mutant mice
    T Jacks
    Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139
    Curr Biol 4:1-7. 1994
    ..The construction of mouse strains carrying germline mutations of p53 facilitates analysis of the function of p53 in normal cells and tumorigenesis...
  76. ncbi Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy
    P Birner
    Institute of Clinical Pathology, University of Vienna, A 1090 Vienna, Austria
    Clin Cancer Res 7:1661-8. 2001
    ..To investigate the impact of expression of hypoxia-inducible factor (HIF)-1alpha on prognosis and on response to chemotherapy in epithelial ovarian tumors...
  77. ncbi p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast
    M Barbareschi
    Department of Pathology, San Martino Hospital, Trento, Italy
    Am J Surg Pathol 25:1054-60. 2001
    ..Furthermore, because p63 immunoreactivity in adult epithelia is normally restricted to progenitor cells, it can be speculated that it might be a clue for the identification of the still elusive breast progenitor cells...
  78. ncbi p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis
    Stefan Kubicka
    Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Germany
    Dig Dis Sci 47:114-21. 2002
    ..pylori infection. The fact that p53 mutations were significantly correlated with poor survival of patients after potentially curative resection of gastric cancer may have clinical implications for multimodal therapies...
  79. ncbi Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types
    Wei Min Gao
    Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Lung Cancer 40:141-50. 2003
    ..Mutation in p53 was not found to be related to patient survival in this group of patients, while tumor size and degree of differentiation were poor survival predictors...
  80. ncbi Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
    K Lundgren
    Cell Cycle Project, Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA
    Genes Dev 11:714-25. 1997
    ..Additionally, multiple lines of BLGMDM2 transgenic mice developed mammary tumors, confirming that overproduction of MDM2 contributes to tumorigenesis in epithelial cells in vivo...
  81. ncbi The p53 tumor suppressor gene: from molecular biology to clinical investigation
    T Soussi
    Institut Curie, Laboratoire de Génotoxicologie des tumeurs, Paris, France
    Ann N Y Acad Sci 910:121-37; discussion 137-9. 2000
    ..Several studies have shown that p53 mutations are associated with short survival in colorectal cancer, but the use of p53 as a tumoral marker is still a matter of debate...
  82. ncbi Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis
    Genevieve A Andrews
    Department of Otolaryngology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Head Neck 26:870-7. 2004
    ..Mutation of p53 is one of the most common genetic alterations in squamous cell carcinomas of the head and neck (SCCHN). We hypothesized that p53 mutation is associated with Bcl-2 expression and susceptibility to apoptosis in SCCHN...
  83. pmc p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis
    S F Zerp
    Department of Clinical Oncology, University Hospital, Leiden, The Netherlands
    Br J Cancer 79:921-6. 1999
    ....
  84. ncbi A candidate precursor to serous carcinoma that originates in the distal fallopian tube
    Y Lee
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Pathol 211:26-35. 2007
    ....
  85. ncbi Cooperative tumorigenic effects of germline mutations in Rb and p53
    B O Williams
    Department of Biology, Massachusetts Institute of Technology, Cambridge 02139
    Nat Genet 7:480-4. 1994
    ..These data indicate that mutations in Rb and p53 can cooperate in the transformation of certain cell types in the mouse...
  86. ncbi Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes
    Mariano J Scian
    Department of Biochemistry and the Massey Cancer Center, Virginia Commonwealth University, PO Box 980614, Richmond, VA 23298, USA
    Oncogene 23:4430-43. 2004
    ..The results presented here provide some evidence of a possible mechanism for mutant p53-mediated transactivation...
  87. ncbi Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
    Yun Wang
    Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo, Norway
    Hum Mutat 24:21-34. 2004
    ..008) and tended to increase with increasing FIGO stages (P=0.05), but had no significant effect on survival. No association between p63 protein accumulation and TP53 protein accumulation was seen...
  88. ncbi A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare
    R Kumar
    Department of Biosciences, Center for Nutrition and Toxicology, Karolinska Institute, Novum, Huddinge, Sweden
    Int J Cancer 95:388-93. 2001
    In this report we present the results of mutational analysis of the CDKN2B, CDKN2C, CDK4, p53 genes and 5'UTR of the CDKN2A gene in a set of 44 sporadic primary melanomas, which had been earlier analysed for mutations in the CDKN2A (p16/..
  89. ncbi p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy
    Robyn P M Saw
    Department of Surgery, Royal Prince Alfred Hospital, Sydney, Australia
    Dis Colon Rectum 46:192-202. 2003
    ....
  90. ncbi The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas
    Ling Ling Hsieh
    Department of Public Health, Chang Gung University, Tao Yuan 333, Taiwan
    Cancer Epidemiol Biomarkers Prev 12:439-43. 2003
    ..This study also suggests an important role for the XRCC1 399Gln polymorphism in p53 gene mutation in Taiwanese OSCCs...
  91. ncbi Pathways of apoptotic and non-apoptotic death in tumour cells
    Hitoshi Okada
    Institute for Breast Cancer Research Ontario Cancer Institute, 620 University Avenue, Toronto, Ontario, Canada M5G 2C1
    Nat Rev Cancer 4:592-603. 2004
  92. pmc TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer
    Daniela Kandioler
    Department of Surgery, University of Vienna, Vienna, Austria
    Ann Surg 235:493-8. 2002
    ..To evaluate and compare the predictive power of p53 gene analysis versus p53 immunohistochemical staining in terms of response to preoperative short-term radiotherapy using 25 Gy in operable rectal cancer...
  93. ncbi Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation
    Tadahisa Shono
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 62:1069-76. 2002
    ..These results suggest that phosphorylation of p53 at serine 15 and serine 20 is critical for apoptosis induction in p53 gene therapy for gliomas...
  94. pmc Identification and characterization of a p53 homologue in Drosophila melanogaster
    S Jin
    Laboratory of Cancer Biology, Genetics, and Molecular Biophysics, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:7301-6. 2000
    ..It appears that p53 is structurally and functionally conserved from flies to mammals. Drosophila will provide a useful genetic system to the further study of the p53 network...
  95. ncbi p21/CDKN1A mediates negative regulation of transcription by p53
    Kristina Löhr
    Institut fur Virologie, Philipps Universitat Marburg, Robert Koch str 17, 35037 Marburg, Germany
    J Biol Chem 278:32507-16. 2003
    ..Taken together, these results strongly suggest that increased expression of p21/CDKN1A is necessary and sufficient for the negative regulation of gene expression by p53...
  96. ncbi The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis
    M E Smela
    Department of Chemistry and Division of Bioengineering and Environmental Health Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Carcinogenesis 22:535-45. 2001
    ..In addition, epidemiological and experimental data are examined regarding the synergistic effects of AFB(1) and HBV on HCC formation and the predominance of one hotspot GC-->TA transversion in the p53 gene of affected individuals...
  97. ncbi Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
    C Deng
    Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 82:675-84. 1995
    ..These results establish the role of p21CIP1/WAF1 in the G1 checkpoint, but suggest that the anti-apoptotic and the anti-oncogenic effects of p53 are more complex...
  98. ncbi Regulation of p53: intricate loops and delicate balances
    Moshe Oren
    Department of Molecular Cell Biology, The Weizmann Institute of Science, P O Box 26, Rehovot, Israel
    Biochem Pharmacol 64:865-71. 2002
    ..Genetic alterations characteristic of cancer are capable of severely distorting this balance, thereby overriding the tumor suppressor effects of p53 in a manner that facilitates neoplastic conversion...
  99. ncbi Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
    Thomas M Rippin
    Cambridge University Chemical Laboratory and Cambridge Center for Protein Engineering, MRC Centre, Hills Road, Cambridge CB2 2QH, UK
    Oncogene 21:2119-29. 2002
    ..One of the unstable mutants that was reported to have been rescued by CP-31398, R249S, does not bind DNA when folded at lower temperatures...
  100. pmc Expression of p53 isoforms in squamous cell carcinoma of the head and neck
    Linda Boldrup
    Department of Medical Biosciences Pathology, Building 6M, 2nd Floor, Umea University, SE 901 85 Umea, Sweden, and Ninewells Hospital, Dundee, UK
    Eur J Cancer 43:617-23. 2007
    ..Improvements in methodologies and reagents to detect and quantify p53 isoform expression in clinical material will be required to correlate p53 status with clinical outcomes...
  101. ncbi Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods
    Ming Lan Lu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:171-9. 2002
    ..015), and it appears to be a significant prognostic factor associated with patient survival...

Research Grants62

  1. BRCA1 and progesterone receptors in breast cancer
    Eva Y Lee; Fiscal Year: 2013
    ..We have established a mouse model in which specific ablation of BRCA1 as well as p53 genes occurred in the mammary epithelial cells by WAP promoter...
  2. Chemoprevention by black raspberry in oral cancer induced by DB[a,l]P in mice
    KARAM E EL-BAYOUMY; Fiscal Year: 2013
    ..Mutations in both lacI and p53 genes in oral tissues of mice treated with DB[a,l]P are similar to those observed in OSCC in humans...
  3. Etiologic Role of HPV in Keratinocyte Carcinomas
    Margaret Karagas; Fiscal Year: 2009
    ..presence of HPV DNA in tumor tissue and examine constitutional genetic variation in \beXRCC1, EVER1, EVER2 and p53 genes as potential modifiers of SCC susceptibility related to HPV infection...
  4. CDX2 TUMOR SUPPRESSOR PATHWAY DEFECTS IN COLON CANCER
    Eric Fearon; Fiscal Year: 2009
    ..Recent studies in CRC show that whereas the APC (adenomatous polyposis coli), KRAS, and p53 genes are each frequently altered, many other genes are each mutated in only a subset of CRCs...
  5. ALTERED PROTEOGLYCAN GENE EXPRESSION AND CANCER
    Renato V Iozzo; Fiscal Year: 2013
    ..targeted disruption of decorin develop spontaneous colon tumors and mice with a double knock out of decorin and p53 genes die rapidly of thymic lymphomas, indicating that lack of decorin is permissive for tumorigenesis...
  6. Impact of BRG1 Loss in Lung Cancer Development
    David N Reisman; Fiscal Year: 2012
    ..3) We will determine if inactivation of BRG1 and BRM precludes the need for these tumors to alter expression of p16/Rb, and p19/p53 genes (Aims 3 and 4).
  7. GENE EXPRESSION IN CTCL PATIENTS IN IL 12 CLINICAL TRIAL
    Louise Showe; Fiscal Year: 2001
    ..An understanding of the genetic events that lead to tachyphylaxis could provide clues to alternate interim therapies that might reinduce IL-12 responsiveness. ..
  8. Novel Methods for Molecular Analysis of Colorectal Polyps
    James Han; Fiscal Year: 2006
    ..high throughput techniques for scanning of mutations in key CRC-associated genes including the APC, K-Ras and P53 genes from polyp DNA...
  9. DNA STRAND BREAKS AND THE GENETIC BASIS OF LYMPHOMAS
    Gilbert Chu; Fiscal Year: 2001
    ..The signal for cell cycle arrest requires the ATM and p53 genes, which are mutated in at ataxia telangiectasia and Li-Fraumeni syndrome...
  10. MOLECULAR EVENTS IN BLAST CRISIS OF CML
    Martin Cline; Fiscal Year: 1993
    ..diffentiation of hematopoietic cells will be examined utilizing expression vectors containing normal and altered p53 genes. The normal controls of p53 transcription will be examined utilizing DNA footprinting and protein expression ..
  11. INTERACTION OF APC AND P53 IN COLORECTAL CARCINOGENESIS
    Satya Narayan; Fiscal Year: 2001
    ..Development of colon cancer is a multistep process that frequently involves mutations in both the APC and p53 genes. Our preliminary results indicate that expression of APC mRNA is transcriptionally activated in a p53-dependent ..
  12. A NON MAMMALIAN MODEL FOR HUMAN ALL
    Charles Walker; Fiscal Year: 2001
    ..cells (which do not divide in these organisms) and; d) Clams have highly conserved homologs for human c-ras and p53 genes. Homologs for p53 have not yet been identified in any other non-vertebrate models, including yeast...
  13. Involvement of APC in DNA Repair
    Satya Narayan; Fiscal Year: 2006
    ..of colorectal cancer, and is followed by sequential mutations in K-ras, deleted in colorectal cancer (DCC) and p53 genes. How mutation of the APC gene leads to the mutation of other genes is unclear...
  14. MECHANISMS OF P53 DEPENDENT APOPTOSIS
    H Ruley; Fiscal Year: 2000
    ..progression will be determined by comparing tumor induction in wild type mice and mice that lack functional p53 genes. To test whether tumor suppressing functions of p53 are engaged by PU...
  15. DNA DAMAGE BY BIOACTIVATED XENOBIOTICS
    J States; Fiscal Year: 2000
    ..The distribution of DNA damage within the HPRT and p53 genes will be monitored by ligation mediated - PCR (LM-PCR)...
  16. GENETIC ALTERATIONS IN PUVA INDUCED SKIN CANCERS
    HONNAVARA ANANTHASWAMY; Fiscal Year: 1999
    ..Mutations in ras and p53 genes will be identified by single strand conformation polymorphism analysis and nucleotide sequencing...
  17. BK Virus as a Co-Factor in Prostate Cancer
    Michael Imperiale; Fiscal Year: 2009
    ..Mutations in the retinoblastoma susceptibility (RB1) and p53 genes occur rarely or late, respectively, during prostate cancer progression, indicating that a virus which interferes ..
  18. Validation of Biomarkers in Humans Exposed to PAHs
    Qingshan Qu; Fiscal Year: 2004
    ..In addition, the polymorphisms of genes, including CYP1A1, microsomal epoxide hydrolase (mEH), GSTM1, and p53 genes, will be identified to assess gene-environment interactions...
  19. CELLULAR TARGETS OF EARLY BREAST TUMORIGENESIS
    Vimla Band; Fiscal Year: 1999
    ..Surprisingly, selective elimination of p53 function by introduction of dominant-negative mutant p53 genes or SV-40 large T gene failed to immortalize MECs...
  20. BCL-2 FAMILY AND P53 GENES ALTER APOPTOSIS IN GLIOMAS
    Keith Rich; Fiscal Year: 2001
    ..This strategy will allow for the determination of the importance of functional p53, and its interactions with members of the bcl-2 gene family in determining response to both traditional and new chemo- and radio-therapy treatments. ..
  21. CHARACTERIZATION OF NEW HUMAN P53 DISSOCIATORS
    Rainer Brachmann; Fiscal Year: 2004
    ..of p53 will be pursued further by checking for their overexpression in cancer cell lines with wild-type p53 genes and by setting up reverse two-hybrid assays to screen for drugs able to abrogate their effect on p53...
  22. TECHNOLOGY FOR DETECTION OF SINGLE BASE MUTATIONS
    Marianna Goldrick; Fiscal Year: 1992
    ..This new technology will be tested using a series of p53 genes single-base mutations.
  23. NOVEL CARCINOGEN INDUCED CELL CYCLE CHECKPOINT
    Cyrus Vaziri; Fiscal Year: 2001
    ..The Rb and p53 genes play important roles in guarding against malignancy and are mutated or absent in many human cancers...
  24. GENE TRANSFER FOR SUPPRESSION OF THE TUMOR PHENOTYPE
    Theodore Friedmann; Fiscal Year: 1993
    ..We wish to use the models of the retinoblastoma (Rb) and p53 genes to examine the effect of expression of wild type and mutant forms of these tumor suppressor genes on cell ..
  25. Phenotype and Gene Expression in Odontogenic Tumors
    JOHN T WRIGHT; Fiscal Year: 2010
    ..RAS and p53 genes will be sequenced for mutations to discover molecular initiators of tumorigenesis...
  26. IDENTIFYING GENOME CHANGES IN CANCER DEVELOPMENT
    Francis Barany; Fiscal Year: 2000
    ..As a model system, we plan to quantify gene amplification or loss of heterozygosity in the c-myc, K-ras, APC and p53 genes in microdissected tissue from colon tumors using LDR and DNA arrays...
  27. PLASMA PURINE RATIO--A NEW BIOMARKER FOR CANCER RISK
    James Sherley; Fiscal Year: 2002
    ..Due to related mechanisms, the same phenotype may also be at cause for cancers in patients with normal germline p53 genes. A proposal is made to develop a specific indicator of constitutional rGNP-production rate called the plasma to ..
  28. PCBs Target p53 Family Expression in Embryos
    Carol Reinisch; Fiscal Year: 2004
    ..Based upon these new data, the primary purpose of this application is to define the role of four p53 genes, to investigate the differential expression of these four genes, and to define the impact of PCB exposure on ..
  29. FATTY ACID SYNTHESIS AND THE CELL CYCLE
    Ellen Pizer; Fiscal Year: 2001
    ..of p53 on FA synthesis by introduction of either constitutive or temperature sensitive dominant negative mutant p53 genes into cancer cells with wild type p53...
  30. Ultrasensitive Nanoscale Magnetic Sensors for Label-free Analysis of Cancer
    Song Jin; Fiscal Year: 2009
    ..and understand the magnetic property changes upon applying complementary target oligonucleotides from p53 genes to surface modified nanomaterials using a SQUID magnetometer;4) construct integrated sensor devices using ..
  31. A NEURAL TRANSCRIPTION FACTOR IN LUNG CANCER EVOLUTION
    Douglas Ball; Fiscal Year: 2006
    ..models, we will further explore the mechanisms whereby hASH1 can cooperate with individual loss of the Rb and p53 genes to promote hyperplasia, tumorigenesis, and NE transdifferentiation...
  32. Characterization of MBD3L1 and MBD3L2
    GERD PFEIFER; Fiscal Year: 2008
    ..Since both proteins are likely functioning as transcriptional regulators, it will be important to determine if there are changes in gene expression patterns in Mbd311 and Mbd312 (-/-) cells. ..
  33. DNA methylation in cancer genomes
    GERD PFEIFER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  34. FUNCTIOINAL ANALYSIS OF THE P53 TUMOR SUPPRESSOR
    Moshe Oren; Fiscal Year: 2002
    ..Finally, p53 activity will be monitored in vivo in transgenic reporter mice subjected to ischemia. P53 may play a role as a mediator of tissue damage in this clinically important condition. ..
  35. UV DAMAGE, REPAIR AND MUTAGENESIS
    GERD PFEIFER; Fiscal Year: 2003
    ..abstract_text> ..
  36. Progestogen Inhibition of Ovarian Cancer Cell Metastasis
    William Murdoch; Fiscal Year: 2003
    ....
  37. RASSF1 Tumor Suppressor Gene
    GERD PFEIFER; Fiscal Year: 2005
    ..The effect of RASSF1 expression on RAS signaling pathways will be studied. We will examine if RASSF1A, alone or in combination with activated RAS, induces cell death (apoptosis). ..
  38. Senescence and Longevity Modulating Genes, WRN and BLM
    Judith Campisi; Fiscal Year: 2008
    ..Our studies will provide important insights into how WRN and BLM postpone the development of aging phenotypes and the development of cancer in humans. ..
  39. Role of WRN in Longevity Assurance
    Judith Campisi; Fiscal Year: 2008
    ..abstract_text> ..
  40. Mechanisms of chemopreventive effect of resveratrol
    Zigang Dong; Fiscal Year: 2009
    ..Our long-term goal is to identify the molecular mechanism explaining the anti-tumor effect exhibited by resveratrol. Such knowledge will help in developing better chemopreventive agents with fewer side effects. ..
  41. Study on Ultraviolet-induced Signal Transduction
    Zigang Dong; Fiscal Year: 2010
    ..These preclinical studies are designed to lead to the development of new strategies for the chemoprevention of human skin cancers. ..
  42. Hormonal regulation of p53 activity in mammary tissue
    D Jerry; Fiscal Year: 2008
    ..The results will lead to identification of cellular mechanisms that regulate p53 function in the mammary epithelium. These pathways will provide novel targets for both treatment and prevention of breast cancer. ..
  43. Genetic modifiers of mammary tumor susceptibility
    D Jerry; Fiscal Year: 2009
    ..Identificationofgenes thatmodifysusceptibilitytomammarytumors willprovidemarkers for riskassessment andnovel targets for therapeutic intervention. ..
  44. Development of Statistical Approaches Allowing for Genetic Covariates
    Chih Chieh Wu; Fiscal Year: 2008
    ..The Texas Cancer Genetic Consortium, a Cancer Genetic Network regional center, will provide the breast cancer data. [unreadable] [unreadable] [unreadable]..
  45. DIET AND SOMATIC MUTATIONS IN COLON CANCER
    MARTHA OR MARTY SLATTERY; Fiscal Year: 2007
    ..e. p53, K-ras, and microsatellite instability). Differences in colon and rectal tumors will be compared. Additionally data from rectal tumors will be combined with that from colon tumors to define disease pathways. ..
  46. Profiling Modifications of p53 by Mass Spectrometry
    D Jerry; Fiscal Year: 2003
    ..Optimized procedures will be applied to human tumors to determine the patterns of post-translational modifications by MALDI-ToF. ..
  47. FOUR-CORNERS BREAST AND ENDOMETRIAL CANCER STUDY
    MARTHA OR MARTY SLATTERY; Fiscal Year: 2003
    ..C-peptide, glycosylated hemoglobin, IGF-1, and IGFBP3 will be evaluated with respect to breast and endometrial cancer in a subset of women. ..
  48. Anticarcinogenic Mechanisms of Tea Constituents
    Zigang Dong; Fiscal Year: 2007
    ....
  49. TELOMERE DYSFUNCTION, GENOMIC INSTABILITY AND CANCER
    Steven Artandi; Fiscal Year: 2005
    ..Transplantation experiments using this model will reveal if the effect on tumor biology is a cell autonomous one. ..
  50. P53-dependent responses to toxicants in parous and nulliparous breast
    D Joseph Jerry; Fiscal Year: 2010
    ....
  51. Molecular Characterization of Inflammatory Breast Cancer
    AMR SOLIMAN; Fiscal Year: 2006
    ..With the large number of patients included in this study from Egypt and the U.S., we may be able develop a better idea about molecular pathways and prognostic factors in IBC pathogenesis. ..
  52. Growth Factors and Colon Cancer
    MARTHA OR MARTY SLATTERY; Fiscal Year: 2006
    ..This study builds on a unique existing resource to study genetic and environmental associations with colorectal cancer. It will provide insight into colon cancer etiology and therefore avenues to disease prevention. ..
  53. Biomarkers of Heavy Metal Exposure Related to Pancreatic Cancer Genetic Mutations
    AMR SOLIMAN; Fiscal Year: 2007
    ..The results from this study will provide clues about the etiology of pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  54. Regulation of the von Hippel-Lindau Protein
    Paul Corn; Fiscal Year: 2007
    ..abstract_text> ..
  55. Molecular basis of arsenic-induced cell transformation
    Zigang Dong; Fiscal Year: 2007
    ..Such knowledge will facilitate the design of more effective and specific strategies with fewer side effects for chemoprevention of arsenic-induced cancer. ..
  56. MOLECULAR STAGING AND SCREENING OF LUNG CANCER
    Steven Ahrendt; Fiscal Year: 2002
    ..Completion of the proposed mentored training period will provide the candidate with an excellent foundation for pursuing his long-term goals in academic surgical oncology. ..
  57. A PROSPECTIVE STUDY OF ALASKA NATIVES & AMERICAN INDIANS
    MARTHA OR MARTY SLATTERY; Fiscal Year: 2006
    ..The AIAN cohort will serve as a resource to enhance research and training activities of AIAN students interested in health research, health education, and general public health. ..
  58. Novel Functions for Telomerase Enzyme Complex in Vivo
    Steven Artandi; Fiscal Year: 2005
    ..Through analysis of a conditional knockout mouse, we will determine the role of endogenous telomerase in cells in culture and in stern/progenitor compartments in vivo. ..
  59. Epidemiology of Colon Cancer in a Special Population
    AMR SOLIMAN; Fiscal Year: 2006
    ..Together, the training in these three areas will provide the skills and experience necessary for an independent career as a molecular and genetic epidemiologist interested in colorectal cancer. ..
  60. Diagnostic Assays of p53 DNA Binding Activity
    Susannah Gal; Fiscal Year: 2004
    ..These approaches are general enough to be applied to a number of DNA binding proteins associated with other important human diseases. ..
  61. INHIBITION OF CARCINOGENESIS BY TEA AND TEA CONSTITUENTS
    Zigang Dong; Fiscal Year: 2010
    ..abstract_text> ..
  62. Factors Associated with Age-Related Maculopathy
    Hong Lai; Fiscal Year: 2006
    ..Our goal is to generate new hypotheses for further research on ARM. [unreadable] [unreadable]..